| Cardiovascular efficacy and safety of bococizumab in high-risk patients PM Ridker, J Revkin, P Amarenco, R Brunell, M Curto, F Civeira, ... New England Journal of Medicine 376 (16), 1527-1539, 2017 | 653 | 2017 |
| Diabetes dyslipidemia JD Schofield, Y Liu, P Rao-Balakrishna, RA Malik, H Soran Diabetes therapy 7, 203-219, 2016 | 457 | 2016 |
| Volanesorsen and triglyceride levels in familial chylomicronemia syndrome JL Witztum, D Gaudet, SD Freedman, VJ Alexander, A Digenio, ... New England Journal of Medicine 381 (6), 531-542, 2019 | 423 | 2019 |
| Lysosomal acid lipase deficiency–an under-recognized cause of dyslipidaemia and liver dysfunction Ž Reiner, O Guardamagna, D Nair, H Soran, K Hovingh, S Bertolini, ... Atherosclerosis 235 (1), 21-30, 2014 | 362 | 2014 |
| Triglyceride lowering with pemafibrate to reduce cardiovascular risk A Das Pradhan, RJ Glynn, JC Fruchart, JG MacFadyen, ES Zaharris, ... New England Journal of Medicine 387 (21), 1923-1934, 2022 | 327 | 2022 |
| Obesity: a critical risk factor in the COVID‐19 pandemic S Kwok, S Adam, JH Ho, Z Iqbal, P Turkington, S Razvi, CW Le Roux, ... Clinical obesity 10 (6), e12403, 2020 | 293 | 2020 |
| Hypercholesterolaemia and its management D Bhatnagar, H Soran, PN Durrington Bmj 337, 2008 | 279 | 2008 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 247 | 2019 |
| Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset … FJ Raal, GK Hovingh, D Blom, RD Santos, M Harada-Shiba, E Bruckert, ... The lancet Diabetes & endocrinology 5 (4), 280-290, 2017 | 247 | 2017 |
| Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy MP McGowan, JC Tardif, R Ceska, LJ Burgess, H Soran, I Gouni-Berthold, ... PloS one 7 (11), e49006, 2012 | 243 | 2012 |
| Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies B Williams, TM MacDonald, SV Morant, DJ Webb, P Sever, GT McInnes, ... The lancet Diabetes & endocrinology 6 (6), 464-475, 2018 | 225 | 2018 |
| Familial hypercholesterolaemia: a global call to arms AJ Vallejo-Vaz, SRK Seshasai, D Cole, GK Hovingh, JJP Kastelein, ... Atherosclerosis 243 (1), 257-259, 2015 | 205 | 2015 |
| HEART UK consensus statement on Lipoprotein (a): A call to action J Cegla, RDG Neely, M France, G Ferns, CD Byrne, J Halcox, D Datta, ... Atherosclerosis 291, 62-70, 2019 | 200 | 2019 |
| Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile … R Aghamohammadzadeh, AS Greenstein, R Yadav, M Jeziorska, S Hama, ... Journal of the American College of Cardiology 62 (2), 128-135, 2013 | 192 | 2013 |
| Overview of the current status of familial hypercholesterolaemia care in over 60 countries-The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) AJ Vallejo-Vaz, M De Marco, CAT Stevens, A Akram, T Freiberger, ... Atherosclerosis 277, 234-255, 2018 | 190 | 2018 |
| Variation in paraoxonase-1 activity and atherosclerosis H Soran, NN Younis, V Charlton-Menys, P Durrington Current opinion in lipidology 20 (4), 265-274, 2009 | 183 | 2009 |
| HDL functionality H Soran, S Hama, R Yadav, PN Durrington Current opinion in lipidology 23 (4), 353-366, 2012 | 179 | 2012 |
| Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ... The Lancet 398 (10312), 1713-1725, 2021 | 176 | 2021 |
| Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an “FCS score” P Moulin, R Dufour, M Averna, M Arca, AB Cefalù, D Noto, L D'Erasmo, ... Atherosclerosis 275, 265-272, 2018 | 169 | 2018 |
| Antioxidant properties of HDL H Soran, JD Schofield, PN Durrington Frontiers in pharmacology 6, 222, 2015 | 169 | 2015 |
